Helix private placement to total C$11.4M

Helix BioPharma has received subscriptions for the purchase, by way of a private placement, of a total of 6,800,000 units at $1.68 per unit, for gross proceeds totaling C$11.4 million ($11.0 million). The company anticipates closing the placement within the next 10 days.

Each unit consists of one common share and one-half of one common share purchase warrant, with each one of the latter entitling the holder to buy one common share at a price of $2.36 for up to three years after the closing date of the private placement.